BNTC Benitec Biopharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1808898 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-18.4%
TTM EPS YoY4.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-37.6%
ROA-36.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio19.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-23.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $75,000 | $73,000 |
| R&D expense | $23.39M | $18.33M | $15.61M | $12.77M | $11.27M |
| SG&A expense | $27.80M | $23.43M | $6.99M | $6.38M | $6.65M |
| Operating income | -$51.19M | -$41.77M | -$22.49M | -$19.08M | -$17.85M |
| Pretax income | -$45.34M | -$37.18M | -$21.04M | -$18.95M | -$17.37M |
| Income tax | $0 | — | — | — | — |
| Net income | -$45.55M | -$37.92M | -$21.75M | -$19.56M | -$18.21M |
| EBITDA | -$51.13M | -$41.70M | -$22.40M | -$18.95M | -$17.69M |
| EPS (basic) | -0.98 | -1.05 | -1.22 | -14.12 | -37.88 |
| EPS (diluted) | -0.98 | -1.05 | -1.22 | -14.12 | -37.88 |
| Weighted avg. shares (diluted) | 46.56M | 36.21M | 18.36M | 1.39M | 480,688 |
| Balance sheet | |||||
| Cash & equivalents | $179.97M | $97.86M | $50.93M | $2.49M | $4.08M |
| Current assets | $181.69M | $98.52M | $51.67M | $3.73M | $4.82M |
| PP&E, net | $178,000 | $131,000 | $179,000 | $87,000 | $222,000 |
| Total assets | $182.62M | $99.59M | $52.21M | $4.46M | $5.97M |
| Current liabilities | $5.34M | $1.80M | $4.92M | $3.98M | $2.53M |
| Total liabilities | $5.61M | $2.30M | $4.96M | $4.26M | $3.09M |
| Shareholders' equity | $177.01M | $97.30M | $47.25M | $202,000 | $2.88M |
| Shares outstanding | 34.42M | 26.25M | 10.09M | 1.67M | 480,688 |
| Cash flow statement | |||||
| Operating cash flow | -$16.52M | -$23.59M | -$19.40M | -$18.01M | -$15.90M |
| Capital expenditure | $105,000 | $18,000 | $179,000 | $1,000 | $13,000 |
| Free cash flow | -$16.62M | -$23.61M | -$19.58M | -$18.01M | -$15.91M |
| Investing cash flow | -$105,000 | -$18,000 | -$179,000 | -$1,000 | -$13,000 |
| Financing cash flow | $98.98M | $70.48M | $68.03M | $16.02M | — |
| Depreciation & amortization | $58,000 | $66,000 | $87,000 | $136,000 | $167,000 |
| Stock-based compensation | $26.41M | $17.43M | $830,000 | $452,000 | $870,000 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.